

**Enterprise Pharmacy and Therapeutics Committee Meeting**  
**Call in number 646-876-9923 Meeting ID 831-139-3271**  
**October 25<sup>th</sup>, 2021**  
**5:00PM-7:00PM CST**

Pre-register at [jplante1@amerihealthcaritasla.com](mailto:jplante1@amerihealthcaritasla.com) prior to the meeting

<u><b>Subject</b></u>	<u><b>Presenter</b></u>
1. Call to Order	B. Himmelstein
2. Conflict of Interest Disclosures	S. Cherian
3. BCC Positive Changes and PA Criteria Updates	C. Meny
4. Review and approval of July P&T and August Proxy minutes	S. Cherian
5. Old Business	PerformRx
A. Medications for the Management of Obesity..... p. 89	
B. Oral Atypical Antipsychotics for Members Below the FDA approved minimum age ..... p. 91	
C. Specialty Drugs PA Criteria ..... p. 93	
D. Continuous Glucose Monitors ..... p. 101	
E. Insulin Pumps ..... p. 103	
6. New Business	PerformRx
A. Biologic Agents for Nasal Polyps ..... p. 106	
B. VEGF Inhibitors for Ophthalmic Conditions ..... p. 108	
C. Epinephrine Auto-Injector ..... p. 112	
D. Specialty Drugs Update ..... p. 113	
E. Ivermectin ..... p. 118	
F. Gabapentin Quantity Limits..... p. 119	
G. Hepatitis C PA criteria..... p. 121	
7. Drug Reviews:	PerformRx
A. Therapeutic Class:	
1. Urinary Antispasmodics ..... p. 125	
2. Multi-vitamins with Fluoride..... p. 130	
3. Fluoride Dental Preps ..... p. 145	
4. Ketone Test Strips ..... p. 153	
5. Topical Steroids ..... p. 159	
6. Androgens ..... p. 173	

B. Single Products:	PerformRx
1. Rezurock.....	p. 184
2. Bylvay .....	p. 191
3. Kerendia .....	p. 200
4. Saphnelo.....	p. 209
8. New Products	PerformRx
9. Prior Authorization Criteria Review:	PerformRx
A. Prior Authorization Criteria Annual Review:	
1. 5-HT3 RA, NK1 RA.....	p. 227
2. Dalfampridine.....	p. 231
3. Danocrine (danazol) .....	p. 233
4. Daraprim (pyrimethamine) .....	p. 235
5. Emergency Use Authorization (EUA) Drugs/Products for COVID-19 .....	p. 237
6. Epidiolex (cannabidiol).....	p. 239
7. Fabrazyme (agalsidase beta) .....	p. 240
8. Formulary Antidiabetic Agents .....	p. 244
9. Gonadotropin Releasing Hormone Agonists (GNRH).....	p. 248
10. Hepatitis C Treatment.....	p. 255
11. Hormone Replacement Therapy.....	p. 273
12. Hydroxyprogesterone Caproate .....	p. 276
13. Immunoglobulins.....	p. 278
14. Brand Name Medication Criteria .....	p. 284
15. Sleep Disorder Therapy .....	p. 290
16. Interleukin Receptor Antagonists for Eosinophilic Conditions .....	p. 305
17. Neuromyelitis Optica Spectrum Disorder (NMOSD) Agents .....	p. 311
18. Oncology Drugs .....	p. 314
19. Pediculicides .....	p. 318
20. Safety Edit Exception Criteria .....	p. 322
21. Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors Combination Productions Containing SGLT-2 Inhibitors.....	p. 337
22. Stimote.....	p. 340
23. Sublingual Allergenic Extracts .....	p. 341
24. Veklury (remdesivir).....	p. 347
25. Xolair for Asthma and Urticaria .....	p. 349
26. Zolgensma .....	p. 352
27. ACDE – Benzodiazepines.....	p. 354
28. ACDE – Injectable Anticoagulants .....	p. 357
29. ACDE – Proton Pump Inhibitors .....	p. 359
30. BCC - Treatment of Hereditary Angioedema .....	p. 361
31. BCC - Retinoic Acid Derivatives for Acne .....	p. 362
32. BCC- Tysabri .....	p. 364

B. Prior Authorization Criteria Annual Review without Clinical Changes

1. Antihyperlipidemia Agents ..... p. 367
2. Cholbam ..... p. 369
3. Ciprodex ..... p. 371
4. Donepezil..... p. 372
5. Endari ..... p. 373
6. Fintepla ..... p. 374
7. Galafold (migalastat)..... p. 375
8. GNRH Receptor Antagonists ..... p. 377
9. Hemangeol (propranolol) ..... p. 379
10. ACLA – Diabetic Testing Supplies ..... p. 380
11. Prior Authorization Exception Criteria ..... p. 381
12. Quantity Limit Exception Criteria..... p. 382
13. Reblozyl ..... p. 384
14. Retinoids (dermatologic) ..... p. 386
15. Sedative Hypnotics ..... p. 390
16. SMN2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy (SMA)..... p. 392
17. Spravato ..... p. 396
18. Step Therapy Exception Criteria ..... p. 398
19. Tardive Dyskinesia ..... p. 399
20. Topical Antiviral Treatment ..... p. 403
21. Zulresso ..... p. 407

10. Additional Items PerformRx

- A. Pneumonia Vaccines ..... p. 409

11. Recalls PerformRx

12. Adjourn B. Himelstein

**\*\*\*NEXT MEETING: January 31<sup>st</sup>, 2022\*\*\***